Study Shows Neulasta Reduced the Incidence of Febrile Neutropenia in Patients With Colorectal Cancer Receiving FOLFOX or FOLFIRI and Bevacizumab /PRNewswire/ -- Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study , a Phase 3 trial which evaluated Neulasta in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for ... (more)
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Amgen-Announces-Results-From-Phase-3-PAVES-Study-E/ArticleNewsFeed/Article/detail/803793?ref=25
http://www.appliedclinicaltrialsonline.com/appliedclinicaltrials/Phase+News/Amgen-Announces-Results-From-Phase-3-PAVES-Study-E/ArticleNewsFeed/Article/detail/803793?ref=25
No comments:
Post a Comment